Identifying and engaging young people early to reduce untreated psychosis duration
Early Stage Identification and Engagement to Reduce the Duration of Untreated Psychosis: Evaluating the Impact of Screening and Systematic Communication
This study is all about finding and helping young people who are having their first experience with psychosis, by using a proven screening method from the Netherlands to make sure they get the right support and treatment as soon as possible.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10894646 on NIH RePORTER |
What this research studies
This research focuses on improving the early identification and treatment of individuals experiencing first episode psychosis (FEP). It aims to adapt a successful screening method from the Netherlands to the U.S. context, enhancing communication about psychosis and treatment options for patients and their families. By screening youth entering mental health services, the study seeks to capture more individuals at high risk for psychosis and connect them quickly to specialized care. The goal is to reduce the duration of untreated psychosis, which often exceeds one year.
Who could benefit from this research
Good fit: Ideal candidates for this research are youth aged 10-21 who are entering mental health services and may be experiencing early signs of psychosis.
Not a fit: Patients who are not experiencing early signs of psychosis or those outside the age range of 10-21 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster treatment for young individuals experiencing psychosis, improving their recovery outcomes.
How similar studies have performed: Previous research in the Netherlands has shown success with similar screening and engagement approaches for early psychosis.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Landa, Yulia — Icahn School of Medicine at Mount Sinai
- Study coordinator: Landa, Yulia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.